CoChat

The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types

Open access
Fancello, Laura, Kampen, Kim R., Hofman, Isabel J.F., Verbeeck, Jelle, Keersmaecker, Kim De · 2017 · Oncotarget
Cited by 122

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Laura Fancello 1,* , Kim R. Kampen 1,* , Isabel J.F. Hofman 1 , Jelle Verbeeck 1 and Kim De Keersmaecker 1 1 KU Leuven-University of Leuven, Department of Oncology, LKI-Leuven Cancer Institute, Leuven, Belgium * These authors have contributed equally to this work Correspondence to: Kim De Keersmaecker, email: // Keywords : ribosomal protein, haploinsufficient tumor suppressor, TCGA, breast cancer Received : January 05, 2017 Accepted : January 11, 2017 Published : January 29, 2017 Abstract For many years, defects in the ribosome have been associated to cancer. Recently, somatic mutations and deletions affecting ribosomal protein genes were identified in a few leukemias and solid tumor types. However, systematic analysis of all 81 known ribosomal protein genes across cancer types is lacking. We screened mutation and copy number data of respectively 4926 and 7322 samples from 16 cancer types and identified six altered genes ( RPL5 , RPL11 , RPL23A , RPS5 , RPS20 and RPSA ). RPL5 was located at a significant peak of heterozygous deletion or mutated in 11% of glioblastoma, 28% of melanoma and 34% of breast cancer samples. Moreover, patients with low RPL5 expression displayed worse overall survival in glioblastoma and in one breast cancer cohort. RPL5 knockdown in breast cancer cell lines enhanced G2/M cell cycle progression and accelerated tumor progression in a xenograft mouse model. Interestingly, our data suggest that the tumor suppressor role of RPL5 is not only mediated by its known function as TP53 or c-MYC regulator. In conclusion, RPL5 heterozygous inactivation occurs at high incidence (11-34%) in multiple tumor types, currently representing the most common somatic ribosomal protein defect in cancer, and we demonstrate a tumor suppressor role for RPL5 in breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14895

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Fancello, L., Kampen, K. R., Hofman, I. J. F., Verbeeck, J., & Keersmaecker, K. D.
Venue
Oncotarget
Published
2017-01-29
Volume
8
Issue
9
Pages
14462-14478
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2583421453
Cited by
122
References
5
FWCI
5.17
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.